1.
In the control group, 26 of 100 people with moderate to severe asthma had an asthma exacerbation over a 16‐ to 60‐week period, compared with 16 (95% CI 13 to 18) of 100 for the omalizumab group.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.